FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Topical Cannabidiol for Established Chemotherapy-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Trial. PMID 39016024 · Cannabis Cannabinoid Res · 2024-Dec This is a Phase II pilot randomized trial evaluating a topical drug (cannabidiol) for chemotherapy-induced neuropathy, which is an oncology-related supportive care condition. However, it fails multiple eligibility criteria: 1) It is explicitly a pilot/Phase II study, not a definitive Phase III/IIIb or Phase II/III trial. 2) It does not have a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS) or Kaplan-Meier/HR analysis; the outcomes are symptom scores (EORTC-CIPN20, etc.). Therefore, it is not eligible for the KM digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer. PMID 38958195 · Asia Pac J Clin Oncol · 2024-Dec The record is an eligible oncology RCT with a drug intervention and a time-to-event efficacy endpoint, but it is explicitly a Phase 4 study, not a Phase III/IIIb or Phase II/III trial as required by the adjudication rules. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. PMID 38940282 · BJU Int · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted Radical Prostatectomy with the KangDuo Surgical System Versus the da Vinci Si System: A Prospective, Double-center, Randomized Controlled Trial. PMID 38862329 · Eur Urol Focus · 2024-Dec The study is a randomized controlled trial in oncology (prostate cancer) with original results, but it compares two surgical robotic systems for radical prostatectomy. It does not involve a drug-containing intervention and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) as a primary or key secondary outcome; the primary outcome is surgical success, and secondary outcomes are short-term functional/oncological measures (e.g., urinary continence, adverse events). Therefore, it does not meet the eligibility criteria for inclusion in this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma. PMID 38839505 · Eur Urol Focus · 2024-Dec Eligible record excluded: The study is a single-arm Phase III trial, not randomized. The abstract explicitly states it is a 'single-arm' study, and the publication types include 'Clinical Trial, Phase III' but not 'Randomized Controlled Trial'. The requirement for randomized trials is not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial. PMID 38737403 · Regen Ther · 2024-Dec The study is a randomized trial but is not oncology-focused (hepatitis C-related cirrhosis, not malignant neoplasm), uses a non-drug cellular therapy, lacks any primary or key secondary time-to-event endpoint (no OS, PFS, etc.), and is exploratory, not definitive Phase III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance). PMID 38716804 · Epigenetics · 2024-Dec The record describes a secondary, post-hoc biomarker analysis of a randomized trial, not the primary report of the trial's efficacy results. While it involves a randomized, drug-intervention oncology study with time-to-event endpoints, it does not meet the 'original formal-result report of a Phase III/IIIb or Phase II/III randomized trial' criterion. The phase is not explicitly confirmed in the metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer. PMID 38653622 · Eur Urol Oncol · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial. PMID 38653621 · Eur Urol Oncol · 2024-Dec The study is an oncology randomized controlled trial comparing two drugs in prostate cancer patients, but it does not include a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The primary outcome is patient preference, and secondary outcomes include side-effect profiles and quality of life. The report is an interim analysis with potentially inconclusive results. Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial. PMID 38407192 · Hematology · 2024-Dec The record is from a Phase III randomized trial with a PFS endpoint, but it is an analysis of CMV serology's prognostic impact, not a report of a drug-containing intervention's primary efficacy results. The drug intervention criterion is not met as the abstract does not establish the trial's intervention or the analysis of drug efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer. PMID 37248723 · Biotechnol Genet Eng Rev · 2024-Dec The record is an oncology randomized controlled trial with a drug intervention and a time-to-event efficacy endpoint (DFS), but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III. The metadata does not provide sufficient evidence to confirm the required trial phase for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of transarterial chemoembolization alone compared to its combination with anlotinib among patients with intermediate or advanced stage hepatocellular carcinoma: a phase II randomized controlled trial. PMID 39279973 · J Gastrointest Oncol · 2024-Aug-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Stereotactic body radiation therapy (SBRT) in patients with hepatocellular cancer-a narrative review and expert opinion. PMID 39279965 · J Gastrointest Oncol · 2024-Aug-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial. PMID 39319400 · Br J Surg · 2024-Aug-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer. PMID 39210431 · Cancer Imaging · 2024-Aug-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Consequences of Spirometry During Military Routine Medical Examinations on Smoking Cessation Compared to Minimal Advice. PMID 38109715 · Mil Med · 2024-Aug-30 The study is a randomized controlled trial in a human population, but it is not an oncology study (it evaluates smoking cessation interventions). It does not involve a drug-containing intervention (only spirometry and minimal advice). The primary endpoint is self-reported tobacco cessation at 6 months, which is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. PMID 38713888 · Blood · 2024-Aug-29 This is a secondary, biomarker-focused analysis (mass spectrometry for MRD) from the ATLAS phase 3 trial, reporting on the prognostic value of MRD negativity for PFS. It is not a primary or key secondary efficacy report of the randomized trial itself. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial. PMID 39191779 · Nat Commun · 2024-Aug-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): Type II Hybrid Implementation Study. PMID 39190468 · J Med Internet Res · 2024-Aug-27 Study is a randomized implementation trial of patient-reported outcome measures in oncology, but it lacks a drug-containing intervention and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The endpoints are health service outcomes (symptom detection, allied health review). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. PMID 38669315 · Blood Adv · 2024-Aug-27 The trial is an oncology RCT with drug intervention and includes survival endpoints. However, it fails the phase3_or_definitive criterion because the record does not explicitly state the trial phase (Phase III, IIIb, or combined II/III). The primary endpoint is cumulative incidence of severe cGVHD, not a time-to-event efficacy endpoint like OS or PFS. Survival (OS, GVHD-free, relapse-free) is reported but as secondary outcomes without HR or Kaplan-Meier details in the provided abstract. Therefore, it does not meet all eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| WONDER-02: plastic stent vs. lumen-apposing metal stent for endoscopic ultrasound-guided drainage of pancreatic pseudocysts-study protocol for a multicentre randomised non-inferiority trial. PMID 39182137 · Trials · 2024-Aug-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Factors influencing fidelity to guideline implementation strategies for improving pain care at cancer centres: a qualitative sub-study of the Stop Cancer PAIN Trial. PMID 39174979 · BMC Health Serv Res · 2024-Aug-22 This is a qualitative sub-study of a Phase III randomized trial for improving cancer pain care. It does not meet the core eligibility criteria: it lacks a drug intervention and a time-to-event efficacy endpoint (the focus is on implementation fidelity, not survival or progression). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. PMID 39174547 · NPJ Breast Cancer · 2024-Aug-22 Meets all eligibility criteria: oncology human RCT, Phase 3, drug-containing intervention (palbociclib), primary time-to-event endpoint (PFS) with HR, and original result report. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 3 Figure · 7 Panel · risk visible |
| Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience. PMID 39195341 · Curr Oncol · 2024-Aug-21 The record is an abstract describing the development and challenges of establishing a clinical trial network for a Phase II/III RCT in prostate cancer. It does not present original trial results with a time-to-event efficacy endpoint. It also describes a non-drug intervention (radiotherapy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. PMID 39168989 · Blood Cancer J · 2024-Aug-21 Meets all required criteria: human oncology, randomized, definitive phase (Phase III/IIIb implied by context of comparing standard conditioning regimens in a multicenter trial), drug intervention, time-to-event endpoints (OS, LFS, GRFS), and original long-term results. Phase evidence inferred from trial design and publication type (Randomized Controlled Trial, Multicenter Study) rather than explicit label, but highly confident it is definitive. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 3 Panel · risk visible |
| Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial. PMID 39164237 · Nat Commun · 2024-Aug-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Aerobic Training for Adverse Symptoms Related to Chemotherapy During Treatment: Protocol for a Randomized Controlled Trial With Cost-Effectiveness Assessment. PMID 39163116 · JMIR Res Protoc · 2024-Aug-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). PMID 38889377 · J Clin Oncol · 2024-Aug-20 命中用户提供的消化道肿瘤阳性参考集。 |
B
|
影子组漏检补回 | eligiblepositive_reference | confirmed 1 Figure · 4 Panel · risk visible |
| Attenuation of DNA base oxidation in post-surgery colorectal stage III patients at subsequent follow-ups. PMID 38762060 · Free Radic Biol Med · 2024-Aug-20 The record describes a biomarker (DNA base oxidation) study nested within a randomized trial (CRC-NORDIET) but is not a primary result report of a definitive trial with a drug intervention and a key time-to-event efficacy endpoint. The abstract focuses on oxidative stress measurements over time, not on a drug intervention's effect on survival or progression. The phase of the parent trial is not explicitly stated, and the study itself is a cross-sectional biomarker follow-up, not the primary report of a randomized trial with a drug intervention and time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study. PMID 39148031 · BMC Cancer · 2024-Aug-15 The record is excluded because it is not a randomized trial; the study is a retrospective analysis of data from a prospective trial, which violates the requirement for a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A seamless phase II/III design with dose optimization for oncology drug development. PMID 38845095 · Stat Med · 2024-Aug-15 The record describes a proposed trial design (protocol) without presenting original results from a randomized controlled trial. It lacks a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. PMID 38703010 · Cancer · 2024-Aug-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. PMID 39193574 · World J Gastroenterol · 2024-Aug-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation. PMID 39134959 · BMC Cancer · 2024-Aug-13 Study is a randomized, oncology trial in human lymphoma patients comparing two drug-containing conditioning regimens with reported OS and PFS results. However, the explicit trial phase (e.g., Phase III) is not confirmed in the provided title, abstract, or metadata, preventing definitive eligibility determination. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. PMID 39128904 · Nat Commun · 2024-Aug-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy. PMID 39127745 · Nat Commun · 2024-Aug-10 The publication is a secondary analysis of biomarker/circulating tumor DNA parameters from a Phase III trial, not a primary or formal result report of the randomized trial itself. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. PMID 39096924 · Lancet · 2024-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. PMID 38833659 · J Clin Oncol · 2024-Aug-10 The study is a randomized Phase III oncology trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) or related analyses (Kaplan-Meier, HR). The primary endpoint (complete response rate) and secondary endpoint (proportion free of nausea) are categorical proportions, not time-to-event outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. PMID 38810208 · J Clin Oncol · 2024-Aug-10 This is a randomized trial in cervical cancer with OS/DFS endpoints, but the intervention is surgical (minimally invasive vs. open radical hysterectomy), not a drug-containing intervention, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. PMID 38771995 · J Clin Oncol · 2024-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. PMID 38701390 · J Clin Oncol · 2024-Aug-10 The record describes an ancillary/prognostic analysis (MRD status) from a randomized trial (STaMINA). While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, the explicit Phase III designation is not confirmed in the metadata. Furthermore, the report type is a secondary/prognostic analysis of the trial, not the primary result report of the randomized treatment comparison. Therefore, eligibility cannot be fully established; phase is uncertain, and it is not a primary result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. PMID 39107131 · J Immunother Cancer · 2024-Aug-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis. PMID 38310565 · J Crohns Colitis · 2024-Aug-06 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study. PMID 38985849 · Oncologist · 2024-Aug-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). PMID 38858106 · Int J Gynecol Cancer · 2024-Aug-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). PMID 38760075 · Int J Gynecol Cancer · 2024-Aug-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy. PMID 39095759 · BMC Cancer · 2024-Aug-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient- vs Physician-Initiated Response to Symptom Monitoring and Health-Related Quality of Life: The SYMPRO-Lung Cluster Randomized Trial. PMID 39186274 · JAMA Netw Open · 2024-Aug-01 The study meets criteria for oncology, human, randomized, original results with a time-to-event endpoint, but fails the core eligibility requirement: it is not a drug-containing intervention trial in a definitive phase (Phase III/IIIb or Phase II/III). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial. PMID 39186271 · JAMA Netw Open · 2024-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early Integrated Palliative Care in Patients With Advanced Cancer: A Randomized Clinical Trial. PMID 39115845 · JAMA Netw Open · 2024-Aug-01 The study is a randomized, controlled trial in advanced cancer patients with a survival endpoint. However, it does not meet key inclusion criteria: 1) It is not a drug-intervention trial (the intervention is an early palliative care program). 2) The trial is not Phase III/IIIb or Phase II/III (the phase is not specified, but the intervention is non-pharmacologic and not a definitive drug efficacy trial). 3) The primary endpoint is quality-of-life, not a time-to-event efficacy endpoint. While survival is reported, it is a secondary endpoint and not statistically significant in the main comparison, and the drug-intervention criterion is not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |